NCT04409002 2025-08-15Niraparib + Dostarlimab + RT in Pancreatic CancerMassachusetts General HospitalPhase 2 Completed18 enrolled 11 charts
NCT04493060 2025-08-07Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic CancerMayo ClinicPhase 2 Completed22 enrolled 17 charts